[HTML][HTML] Stem cell programs in cancer initiation, progression, and therapy resistance
Over the past few decades, substantial evidence has convincingly revealed the existence of
cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly …
cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly …
[HTML][HTML] Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges
MDA Paskeh, F Ghadyani, M Hashemi… - Pharmacological …, 2023 - Elsevier
Cancer progression results from activation of various signaling networks. Among these,
PI3K/Akt signaling contributes to proliferation, invasion, and inhibition of apoptosis …
PI3K/Akt signaling contributes to proliferation, invasion, and inhibition of apoptosis …
[HTML][HTML] Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …
Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy
OS Sarkar, H Donninger, N Al Rayyan, LC Chew… - Science …, 2023 - science.org
Immune checkpoint inhibitor (ICI) therapy is effective against many cancers for a subset of
patients; a large percentage of patients remain unresponsive to this therapy. One …
patients; a large percentage of patients remain unresponsive to this therapy. One …
Pharmacology of adenosine receptors: the state of the art
Adenosine is a ubiquitous endogenous autacoid whose effects are triggered through the
enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Due to the rapid …
enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Due to the rapid …
Targeting immunosuppressive adenosine in cancer
Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1
(PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a …
(PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a …
The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets
Cancers are able to grow by subverting immune suppressive pathways, to prevent the
malignant cells as being recognized as dangerous or foreign. This mechanism prevents the …
malignant cells as being recognized as dangerous or foreign. This mechanism prevents the …
[HTML][HTML] CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
High levels of ecto-5′-nucleotidase (CD73) have been implicated in immune suppression
and tumor progression, and have also been observed in cancer patients who progress on …
and tumor progression, and have also been observed in cancer patients who progress on …
[HTML][HTML] CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization …
XL Ma, MN Shen, B Hu, BL Wang, WJ Yang… - Journal of hematology & …, 2019 - Springer
Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies
worldwide because of rapid progression and high incidence of metastasis or recurrence …
worldwide because of rapid progression and high incidence of metastasis or recurrence …
Immunosuppressive activities of adenosine in cancer
Highlights•Adenosine protects tissues against excessive inflammation and promotes tissue
repair.•The adenosine pathway is hijacked to dampen anti-tumor immunity.•Targeting CD73 …
repair.•The adenosine pathway is hijacked to dampen anti-tumor immunity.•Targeting CD73 …